News | August 27, 2025
SMS Pharmaceuticals receives EIR from USFDA for Central Laboratory Analytical Services
The inspection, conducted from June 23 to June 25, 2025, concluded with zero Form 483 observations
The inspection, conducted from June 23 to June 25, 2025, concluded with zero Form 483 observations
SMS Pharmaceuticals has reported total income of Rs. 196.64 crores during the period ended June 30, 2025
The inspection concluded with zero Form 483 observations
This significant milestone enhances our global regulatory standing
The inspection, conducted from March 17 to March 21, 2025, concluded with one observation in Form 483
SMS Pharmaceuticals has reported total income of Rs. 165.81 crores during the quarter ended June 30, 2024
EDQM conducts GMP inspection of SMS Pharmaceuticals’ API facility
Q2FY24 EBITDA up by 105% y-o-y at Rs. 28 crore
The company has reported total income of Rs. 65.19 crores during the period ended June 30, 2022.
With this, the company can start selling Ibuprofen in the European markets.
Subscribe To Our Newsletter & Stay Updated
